The Clinical safety of Vonoprazan in the Gastric Acid Management, Vono, Docvidya, Gastroenterology, Gastroenterologist, Vonoprazan, Gastric Acid, Gastro
Discerning the clinical safety of vonoprazan over proton pump inhibitors. Explore the safety of vonoprazan in the management of gastric acid complications.
Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that has displayed greater acid suppression compared to proton pump inhibitors (PPIs).1,2
Its peculiar pharmacological properties include stability in the stomach’s acidic environment, good solubility in both acidic and neutral conditions, and a gastric mucosa retention time of 24 hours or more, among others.2
Vonoprazan is approved for various clinical indications, including gastric and duodenal ulcers, erosive esophagitis, Helicobacter pylori eradication, PPI-resistant reflux esophagitis, prevention for recurrence in nonsteroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin ulcer, and prevention of endoscopic submucosal dissection-induced ulcer.3,4
Coming to the safety of the molecule, a meta-analysis revealed that vonoprazan-containing regimens significantly outperformed PPI-containing regimens for Helicobacter pylori eradication (p<0.0001) and also demonstrated significantly lower adverse event (AE) occurrence at 26.4% in vonoprazan groups compared to 33.3% in PPI groups (p=0.008).1 Another prospective observational study involving 1,642 patients with gastrointestinal disorders indicated efficacy of vonoprazan in amelioration of the complications with only 2.3% of patients experiencing AEs which were mild in intensity.5
Let’s hear to what Prof. Hidekazu Suzuki has to say about the clinical safety of Vonoprazan in the gastric acid management.
Conclusion
Vonoprazan, a P-CAB, provides better acid suppression compared to PPIs.1 Along with its significantly higher efficacy in gastrointestinal disorders compared to PPIs, vonoprazan has been reported to be safe with significantly lower AE occurrence.1,5
References
- Dong SQ, Singh TP, Wei X, et al. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Helicobacter. 2017;22(6):e12438.
- Scarpignato C, Hunt RH. Acid suppressant therapy: A step forward with potassium-competitive acid blockers. Curr. Treat. Options Gastroenterol. 2021;19:94–132.
- Veererathinakumar NK, Ananthy V, Codi RS, et al. Potassium-competitive acid blocker: A newer target in the treatment of acid peptic disorder. SBV J. Basic Clin. Appl. Health Sci. 2023;6(2):33–38.
- Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776.
- Abbasi A, Siddiqui SA, Ram B, et al. Real-world evidence to evaluate the efficacy and safety of vonoprazan in gastrointestinal disorders in the Pakistani population. Cureus. 2023;15(11):e48994.
For the use of a registered medical practitioner, hospital or laboratory only.
LMRC Code: GGI-CO-A1-AQS-300041558-APPEMC-G24-1181 DOI of 15/07/24 and DOE of 15/08/24
Vono 20-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
